54 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
GLPG Galapagos NV $115.62 $5.94B N/A
Article Searches
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4257576-galapagos-nv-glpg-ceo-onno-van-de-stolpe-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 28, 2019 - Galapagos NV (NASDAQ:GLPG) Q1 2019 Results Earnings Conference Call April 26, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - VP of IR & Corporate Communications Onno van de Stolpe - Chi
Galapagos NV (GLPG) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/26/galapagos-nv-glpg-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 26, 2019 - GLPG earnings call for the period ending March 31, 2019.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy http://www.zacks.com/stock/news/372671/gilead-files-snda-for-label-expansion-of-hiv-therapy-descovy?cid=CS-ZC-FT-372671 Apr 08, 2019 - Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
2 Incredibly Cheap Pharma Stocks to Buy Now https://www.fool.com/investing/2019/04/01/2-incredibly-cheap-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001 Apr 01, 2019 - Shares of Gilead Sciences and Teva Pharmaceutical Industries are bargains right now.
Gilead & Galapagos Announce Positive Data on Arthritis Drug http://www.zacks.com/stock/news/366666/gilead-galapagos-announce-positive-data-on-arthritis-drug?cid=CS-ZC-FT-366666 Mar 29, 2019 - Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4243438-galapagos-nv-glpg-ceo-onno-van-de-stolpe-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 22, 2019 - Galapagos NV (NASDAQ:GLPG) Q4 2018 Earnings Conference Call February 22, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - Chief Executive Officer Bart
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions http://www.zacks.com/stock/news/344665/amag-up-nearly-10-in-a-year-on-label-expansion-acquisitions?cid=CS-ZC-FT-344665 Dec 27, 2018 - AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status http://www.zacks.com/stock/news/339861/galapagos-osteoarthritis-candidate-gets-fast-track-status?cid=CS-ZC-FT-339861 Nov 28, 2018 - Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids http://www.zacks.com/stock/news/338375/vertex-vrtx-gets-positive-chmp-opinion-for-orkambi-in-kids?cid=CS-ZC-FT-338375 Nov 19, 2018 - CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
What's in the Cards for Bayer (BAYRY) This Earnings Season? http://www.zacks.com/stock/news/336954/whats-in-the-cards-for-bayer-bayry-this-earnings-season?cid=CS-ZC-FT-336954 Nov 12, 2018 - Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.

Pages: 123456

Page 1>